News from us and our partners

Tags

Topics

0 results

News
23 January, 2024
Enthera Pharmaceuticals appoints Lisa M. Olson as CEO and announces clinical trial progress with Ent001
News
22 January, 2024
Pi-Cardia receives FDA Breakthrough Device Designation for ShortCut™
News
19 January, 2024
Sensorion receives approval to start Phase 1/2 trial
News
16 January, 2024
DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing
News
10 January, 2024
Qorium lands additional funds from Brightlands Venture Partners and Sofinnova Partners, as the company sets out on an ambitious growth drive for sustainable leather with the appointment of CEO Michael Newton
News
10 January, 2024
Inventiva draws down €25M second tranche from EIB
News
9 January, 2024
Pyrowave and University of Sherbrooke target cement decarbonization
News
8 January, 2024
NanoPhoria appoints Dr. Suman Shirodkar as chair and Prof. Michael Davidson as non-executive member of the Board of Directors
News
7 January, 2024
Calliditas Therapeutics appoints Maria Törnsén as President North America
News
4 January, 2024
Inspirna licenses ompenaclid to Merck KGaA
News
4 January, 2024
Sofinnova Partners brings in Dr. Joshua Makower, Stanford Biodesign co-founder, as Venture Partner
News
4 January, 2024
Sitryx announces collaboration partner Lilly has commenced a Phase 1 study of SIT-011 for chronic autoimmune and inflammatory diseases
News
2 January, 2024
NanoPhoria Bioscience publishes groundbreaking study in major cardiology journal
News
21 December, 2023
Sofinnova Partners welcomes Andrew M. Weiss as Venture Partner
News
20 December, 2023
Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function
News
18 December, 2023
Industry veteran Abbas Hussain appointed as Chair of Asceneuron

Enthera Pharmaceuticals appoints Lisa M. Olson as CEO and announces clinical trial progress with Ent001

Pi-Cardia receives FDA Breakthrough Device Designation for ShortCut™

Sensorion receives approval to start Phase 1/2 trial

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing

Qorium lands additional funds from Brightlands Venture Partners and Sofinnova Partners, as the company sets out on an ambitious growth drive for sustainable leather with the appointment of CEO Michael Newton

Inventiva draws down €25M second tranche from EIB

Pyrowave and University of Sherbrooke target cement decarbonization

NanoPhoria appoints Dr. Suman Shirodkar as chair and Prof. Michael Davidson as non-executive member of the Board of Directors

Calliditas Therapeutics appoints Maria Törnsén as President North America

Inspirna licenses ompenaclid to Merck KGaA

Sofinnova Partners brings in Dr. Joshua Makower, Stanford Biodesign co-founder, as Venture Partner

Sitryx announces collaboration partner Lilly has commenced a Phase 1 study of SIT-011 for chronic autoimmune and inflammatory diseases

NanoPhoria Bioscience publishes groundbreaking study in major cardiology journal

Sofinnova Partners welcomes Andrew M. Weiss as Venture Partner

Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function

Industry veteran Abbas Hussain appointed as Chair of Asceneuron